Enzyme Linked Immunosorbent Assay (ELISA) News and Research

RSS

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Researchers at the Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, USA, showed that the SARS-CoV-2 spike E484K mutation reduces antibody neutralization.

12 Apr 2021

Autoantibodies may contribute to severe COVID-19 and potential long-COVID-19 symptoms

New research in the USA and China. investigated how autoantibodies could mediate NETs during a COVID-19 infection. Extensive damage to the body from neutrophil extracellular traps (NETs) after infection may be contributing to thromboinflammation and the symptoms experienced by COVID-19 ‘long-haulers’.

8 Apr 2021

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

A recent report published in the New England Journal of Medicine has revealed that the COVID-19 vaccine developed by Moderna, Inc, USA, is capable of inducing robust and durable antibody responses for at least six months post-vaccination.

8 Apr 2021

Single Sputnik V vaccine dose elicits robust immune response in previously infected individuals

A new preprint research paper posted to the medRxiv server describes successful immunization of the vaccinated population with a single dose of the Russian-made Sputnik V vaccine.

29 Mar 2021

New screening method detects cancer biomarkers more effectively

Early screening can mean the difference between life and death in a cancer and disease diagnosis. That's why University of Central Florida researchers are working to develop a new screening technique that's more than 300 times as effective at detecting a biomarker for diseases like cancer than current methods.

26 Mar 2021

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

A team of scientists from the USA and Canada recently characterized the cross-neutralizing potency of anti-SARS-CoV-2 antibodies isolated from COVID-19 patients. The findings reveal that some of the isolated antibodies targeting the spike RBD and the S2 subunit are capable of cross-neutralizing other members of the human beta-coronavirus family.

25 Mar 2021

Detecting SARS-CoV-2 specific IgG antibodies with the Kantaro Covid-SeroKlir Kit

In this interview, Gary Dowthwaite, the Special Projects co-ordinator at EKF Diagnostics, talks to News-Medical about the Kantaro COVID-SeroKlir Kit.

From EKF Diagnostics 24 Mar 2021

Correlation of antibody titers with COVID-19 vaccine efficacy

In a new study the relationship between virus-neutralizing antibody and spike protein-binding IgG antibody levels is explored following vaccination by one of seven currently deployed vaccines. The findings support the use of antibody titers as correlates of protection for COVID-19 vaccines.

23 Mar 2021

Dual-action monoclonal antibodies from an original SARS survivor show promise against COVID-19

A recent study, currently available on the bioRxiv preprint server, indicates that a pair of dual-action monoclonal antibodies derived from an original 2003 SARS survivors could play an important role in the fight against coronavirus disease 2019 (COVID-19) due to their broadly neutralizing activity and the engagement of the immune system via effector function capabilities.

14 Mar 2021

Novel single-particle digital assay using plasmonic nanobubbles

An interdisciplinary team from the University of Texas applied DIAMOND to the respiratory syncytial virus (RSV) diagnostics and demonstrated that DIAMOND is 150 times more sensitive than commercial lateral flow assays. They found that the measurements are completed within 2 minutes. The results of this study are published on the medRxiv* preprint server.

25 Feb 2021

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

Insight into role of aging in response to SARS-CoV-2 infection

Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.

3 Feb 2021

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

A new preprint research paper released on the bioRxiv server discusses the findings from a model that assesses the association between the immunogenicity and protection conferred by a set of adenovirus- (Ad26)-vectored vaccines that express stabilized SARS-CoV-2 spike protein.

3 Feb 2021

Albumin: The Natural Choice for Diagnostic Tests

The availability of established diagnostic kits has enabled researchers to plug-and-play in the design of COVID-19 diagnostics. Such technologies took decades to optimize, but they are now playing an important role in identifying and managing the spread of COVID-19. Recombumin® provides an enhanced solution as part of this toolbox for dealing with this disease

From Albumedix Ltd. 2 Feb 2021

CDC examines COVID-19 outbreak among U.S. office workers: a case study in transmission

Researchers from the Centers for Disease Control and Prevention and the Federal Emergency Management Agency in the U.S. found that despite mitigation efforts, two COVID-19 outbreaks emerged among office workers in Washington, DC.

1 Feb 2021

Moderna vaccine shows robust suppression of SARS-CoV-2 infection in animal model

Researchers have demonstrated that the prime or prime-boost vaccination of Moderna vaccine in hamsters induced robust neutralizing antibodies, ameliorated weight loss, and suppressed SARS-CoV-2 replication in the airways.

28 Jan 2021

Accurate quantitative COVID-19 antibody test kit by EKF

EKF Diagnostics, the global in vitro diagnostics company, announces that it has introduced one of the first tests to precisely measure levels of COVID-19 neutralizing antibodies in individuals.

From EKF Diagnostics 22 Jan 2021

New data on impact of spike mutations and B117 UK variant on neutralization by mAbs and sera

A recent paper by British and Dutch scientists, currently available on the bioRxiv* preprint server, shows that the neutralizing activity of monoclonal antibodies can be dramatically reduced by mutations of the SARS-CoV-2 spike glycoprotein – unlike polyclonal antibodies generated after natural infection that remain active regardless of any introduced amino acid changes.

21 Jan 2021